Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Noxopharm Ltd. ( (AU:NOX) ) has provided an announcement.
Noxopharm Limited announced the successful completion of the first multiple-dose cohort in the HERACLES clinical trial for SOF-SKN™, a novel drug candidate for autoimmune diseases like cutaneous lupus erythematosus. The trial, which is being conducted in Australia, aims to assess the safety and tolerability of SOF-SKN™ through repeated applications, reflecting real-world usage. The trial’s progression to the second and final cohort underscores the drug’s potential impact on the autoimmune disease therapeutics market, which is projected to grow significantly.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company employs its proprietary Sofra™ and Chroma™ technology platforms to enhance mRNA medicines and develop drugs for inflammation, autoimmunity, and oncology.
Average Trading Volume: 96,431
Technical Sentiment Signal: Sell
Current Market Cap: A$28.35M
See more insights into NOX stock on TipRanks’ Stock Analysis page.